Notícias e Atividades da Frazier Life Sciences

Frazier Life Sciences pertence à Frazier Healthcare Partners.

Frazier Healthcare Partners possui 4 subsidiárias incluindo Comprehensive Pharmacy Services, Elevate Patient Financial Solutions e Frazier Life Sciences.

Eles estão dentro:

• Fundo40%
• Equipamentos Médicos20%
• Outro40%

Fusão, aquisição e financiamento envolvendo Frazier Healthcare Partners.

• Frazier Healthcare Partners adquiriu RevSpring (publicado em 14 de março de 2024).

Veja o organograma con seus 34 executivos principais

Biografias mais buscadas da Frazier Life Sciences

• Albert Cha, Co-Managing Partner
• Patrick Heron, Co-Managing Partner
• James Topper, Co-Managing Partner

Recentes movimentos de executivos em Frazier Life Sciences

• Anna Chen antes Principal, foi promovido a Partner  (Notícia publicada em 20 de março de 2025).
• James Li, ingressou na Companhia como Venture Partner  (Notícia publicada em 13 de dezembro de 2024).

Recentes movimentos de executivos em Frazier Healthcare Partners

• Philip Zaorski antes Partner, Growth Buyout, foi promovido a General Partner, Growth Buyout  (Notícia publicada em 5 de março de 2025).

Criar um alerta
para seguir os movimentos de executivos da Frazier Life Sciences.

Frazier Healthcare Partners possui 1.570 concorrentes concorrentes BlackRock (Estados Unidos), Vanguard (Estados Unidos) e Blackstone Group (Estados Unidos).

Popular M&A news in Fundo

• Seven2 has announced the acquisition of HRK Lunis  (publicado em 3 de abril de 2025).
• Fluent adquiriu RIV Capital (publicado em 20 de dezembro de 2024).
• RIV Capital and Fluent have announced they will merge  (publicado em 14 de outubro de 2024)..

Outros contatos sugeridos na indústria do Fundo

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer da Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director da Vanguard
• Hemant Taneja - Chief Executive Officer and Managing Director da General Catalyst Partners

Saiba mais sobre a indústria do Fundo

Últimos comunicados de imprensa de Frazier Life Sciences

• Hillstar Bio Launches with $67 Million Series A Financing to Develop Next Wave of Precision Immunotherapies to Transform Autoimmune Treatment
• Frazier Life Sciences Welcomes Chris Aakre as Principal of Company Creation
• Frazier Life Sciences Promotes Anna Chen to Partner
• Frazier Life Sciences Appoints Gerald Nepom as Senior Advisor
• Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
• First Patient in Phase I/IIa Evaluating ADC TUB-030 · Tubulis News
• Frazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture Partners
• Frazier Life Sciences Appoints Experienced Biotech Innovator and Global Business Leader, James Li, as Venture Partner
• Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550
• Gilead and Tubulis announce agreement on ADC · Tubulis News
• View more press releases Close

Redes sociais sobre Frazier Life Sciences

• Frazier Life Sciences na Wikipedia, Google News e Yahoo Finance
• Frazier Life Sciences na LinkedIn, Twitter e YouTube